Skip to contentI
Inovio Pharmaceuticals, Inc.
I
INOInovio Pharmaceuticals, Inc. Q4 2024 · 10-K
derived · Computed from the longer spans the company filed.
Revenue$116.99K$116.99Kderived+14.0% vs Q4 2023 Net Income-$19.38M-$19.38MderivedN/M vs Q4 2023 EPS, diluted—
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Inovio Pharmaceuticals, Inc. · CIK 1055726 · Engraved from SEC EDGAR
Not derived. Share counts vary by quarter.
Operating Incomederived-$20,369,561N/M Operating Cash Flowderived-$19,663,909N/M Free Cash Flowderived-$19,663,909N/M Margins · derivedOperating margin-17410.8%+9275.8 pt vs Q4 2023
Net margin-16566.4%+7791.8 pt vs Q4 2023
ended Dec 31, 2024 · filed Mar 18, 2025 · 77 d after period end